Volda

This trial investigates gastropexy as a method to reduce gastroesophageal reflux disease GERD symptoms in adults who are morbidly obese and scheduled for laparoscopic sleeve gastrectomy LSG. The study compares two groups to determine whether gastropexy decreases reflux symptoms and objective signs of reflux. LSG is widely used as a bariatric surgery, but it may increase GERD by allowing the stomach remnant to migrate upward into the chest, which this study aims to prevent by using gastropexy. Participants are randomly assigned to receive either sleeve gastrectomy with gastropexy, where the stomach remnant is sutured to the gastrocolic ligament, or sleeve gastrectomy without gastropexy. The study plans to enroll 550 patients. Follow-up visits to assess outcomes are scheduled at six weeks, one year, two years, and five years after surgery. During the study, researchers will monitor the number of participants using acid-reducing medication or those who require reoperations due to GERD over two years. Additional assessments include endoscopic examinations, patient-reported outcomes via questionnaires, and pH-metry tests to measure acid exposure. The study uses double-blind methods and randomization to fairly compare the two groups, with the goal of better understanding the impact of gastropexy on reflux after LSG.

Researchers are conducting an observational study to understand how new immunotherapies are used in treating multiple myeloma and related conditions in Norway. The study aims to fill knowledge gaps, provide evidence for future trials, and help develop guidelines for monitoring and managing side effects to improve patient survival and quality of life. This research focuses on patients with multiple myeloma, primary plasma cell leukemia, and AL amyloidosis. Participants are observed while receiving immunotherapies including Teclistamab, Elranatamab, Talquetamab, Idecabtagene vicleucel, and Ciltacabtagene Autoleucel as part of their routine care outside of clinical trials. The study monitors how these treatments are used in real-world settings, including dosing and administration. There is no assigned treatment group or placebo instead, the study collects data on treatments given during regular healthcare. Throughout the study, participants response to treatment, progression-free survival, time to next treatment, overall survival, and adverse events are tracked for up to ten years. Researchers collect data on infections, antibiotic resistance, airway viruses, and use of antimicrobial prophylaxis during therapy. This long-term monitoring aims to provide comprehensive safety and effectiveness information to guide future care and research.